NORISODRINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORISODRINE (NORISODRINE).
Agonist at beta-1 and beta-2 adrenergic receptors, causing positive inotropic and chronotropic effects on the heart and bronchodilation.
| Metabolism | Metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) in the liver and other tissues. |
| Excretion | Primarily renal excretion of unchanged drug (80-90%) and sulfate conjugates; minor biliary excretion (<5%). |
| Half-life | Terminal half-life is 2-3 minutes; too short for sustained action, requiring continuous IV infusion. |
| Protein binding | Minimal (less than 10% bound to plasma proteins). |
| Volume of Distribution | 0.5-0.8 L/kg; distributes rapidly into total body water. |
| Bioavailability | IV: 100%; IM: 20-40%; Inhalation: 5-10% (due to rapid metabolism in lung and GI tract). |
| Onset of Action | IV: Immediate (seconds); IM: 2-5 minutes; Inhalation: 30 seconds to 1 minute. |
| Duration of Action | IV: 5-10 minutes; IM: 10-20 minutes; Inhalation: 10-15 minutes; due to rapid metabolism. |
Intravenous: 0.5-5 mcg/min continuous infusion; initial rate 0.5 mcg/min, titrate to effect. Subcutaneous or intramuscular: 0.2 mg (0.2 mL of 1:1000 solution).
| Dosage form | POWDER |
| Renal impairment | No specific dose adjustment recommended; monitor for toxicity with severe renal impairment. |
| Liver impairment | Not defined for Child-Pugh; use with caution and monitor for adverse effects. |
| Pediatric use | Intravenous: 0.1-1 mcg/kg/min continuous infusion; titrate to desired effect. Subcutaneous: 0.01-0.02 mg/kg (max 0.5 mg). |
| Geriatric use | Start at lower end of dosing range; monitor cardiovascular status closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORISODRINE (NORISODRINE).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Due to the short half-life and poor oral bioavailability, transfer to the infant is likely low, but caution is advised. Avoid use during breastfeeding unless potential maternal benefit outweighs potential infant risks. |
| Teratogenic Risk | Insufficient data in pregnant women; animal reproduction studies have not been conducted. Due to its vasoconstrictive and beta-adrenergic effects, there is a potential risk of reduced uterine blood flow and fetal hypoxia, particularly in the first and third trimesters. Use only if clearly needed, weighing potential benefit against unknown fetal risks. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to norisodrine or any component; coronary artery disease; narrow-angle glaucoma; concurrent use with other sympathomimetics; concurrent use with MAO inhibitors (hypertensive crisis risk); pregnancy category C (risk not excluded).
| Precautions | May cause cardiac arrhythmias, including ventricular fibrillation; use with caution in patients with ischemic heart disease, hypertension, or hyperthyroidism; may increase myocardial oxygen demand leading to angina; tolerance may develop with prolonged use. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and uterine activity during intravenous infusion. Assess fetal heart rate pattern for signs of distress. Monitor for maternal cardiac arrhythmias, hypertension, or hypotension. Observe for signs of pulmonary edema in cases of prolonged administration. |
| Fertility Effects | No specific studies on fertility effects in humans. In animal studies, beta-adrenergic agonists may interfere with ovulation and implantation. Potential for reduced fertility due to altered adrenergic signaling, but clinical significance is unknown. |